Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
作者： F M Marincola , D E White , A P Wise , S A Rosenberg
DOI: 10.1200/JCO.1995.13.5.1110
关键词:
摘要: PURPOSEHere we report the long-term follow-up evaluation of a phase I/II study toxicity and response combination interferon alfa-2a (IFN alpha) interleukin-2 (IL-2) in patients with metastatic cancer.PATIENTS AND METHODSFrom November 1987 through October 1990, 189 were treated 379 courses. IFN alpha (3 x 10(6) U/m2) was administered three times per day as an intravenous (IV) bolus IV IL-2 2.6 IU/m2 (six patients, group 1), 7.8 (32 2), or 11.7 (26 3). Subsequently, dose escalated to 6 U/m2 plus (22 4). Two further dosage schedules tested at (29 5) 15.6 (74 6); however, because alpha-related toxicity, these two groups received once (6 U/m2). A treatment course consisted cycles (maximum, 15 doses cycle) separated by 10-day inte...
elsevier.com
sci-hub.se 参考文章(33)
Oldham Rk, Arnold J, Blumenschein G, Schwartzberg L, Birch R, Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial. Molecular biotherapy. ,vol. 4, pp. 4- 9 ,(1992)
Stephen E. Ettinghausen, Steven A. Rosenberg, Immunotherapy of Murine Sarcomas Using Lymphokine Activated Killer Cells: Optimization of the Schedule and Route of Administration of Recombinant Interleukin-2 Cancer Research. ,vol. 46, pp. 2784- 2792 ,(1986)
S O Sharrow, S A Rosenberg, R J Robb, M T Lotze, L W Frana, In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2 Journal of Immunology. ,vol. 134, pp. 157- 166 ,(1985)
C. A. Y. Seipp, M. C. Custer, S. E. Ettinghausen, S. O. Sharrow, S. A. Rosenberg, A. A. Rayner, M. T. Lotze, Y. L. Matory, In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. Journal of Immunology. ,vol. 135, pp. 2865- 2875 ,(1985)
D R Parkinson, J S Abrams, P H Wiernik, A A Rayner, K A Margolin, D A Van Echo, M Sznol, J P Dutcher, F R Aronson, J H Doroshow, Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. Journal of Clinical Oncology. ,vol. 8, pp. 1650- 1656 ,(1990) , 10.1200/JCO.1990.8.10.1650
S N Bock, R E Lee, B Fisher, J T Rubin, D J Schwartzentruber, J P Wei, D P Callender, J C Yang, M T Lotze, P A Pizzo, A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. Journal of Clinical Oncology. ,vol. 8, pp. 161- 169 ,(1990) , 10.1200/JCO.1990.8.1.161
J A Sparano, R I Fisher, M Sunderland, K Margolin, M L Ernest, M Sznol, M B Atkins, J P Dutcher, K C Micetich, G R Weiss, Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. Journal of Clinical Oncology. ,vol. 11, pp. 1969- 1977 ,(1993) , 10.1200/JCO.1993.11.10.1969
Steven A Rosenberg, James C Yang, Suzanne L Topalian, Douglas J Schwartzentruber, Jeffrey S Weber, David R Parkinson, Claudia A Seipp, Jan H Einhorn, Donald E White, Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2 JAMA. ,vol. 271, pp. 907- 913 ,(1994) , 10.1001/JAMA.1994.03510360033032
Jens Atzpodien, Hartmut Kirchner, The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies. European Journal of Cancer and Clinical Oncology. ,vol. 27, ,(1991) , 10.1016/0277-5379(91)90586-3
Robert P. Whitehead, Robert Figlin, Marc L. Citron, Julia Pfile, Nancy Moldawer, Dilip Patel, Gary Jones, Dan Levitt, Jacob Zeffren, A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma. Journal of Immunotherapy. ,vol. 13, pp. 117- 121 ,(1993) , 10.1097/00002371-199302000-00006